WealthShield Partners’s Blueprint Medicines BPMC Stock Holding History

WealthShield Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16	Closed	-$1K	–	806
2021 Q1	$1K	Buy	+16	New	+$1.6K	﹤0.01%	1097

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

WealthShield Partners's BPMC Position: Q2 2021 in Review

WealthShield Partners sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 16 shares — an estimated $1K sold.

WealthShield Partners first reported a position in BPMC in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

WealthShield Partners reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
WealthShield Partners sold 16 Blueprint Medicines shares in Q2 2021, an estimated $1K.
WealthShield Partners first reported a position in Blueprint Medicines in Q1 2021 and held it in 1 quarter.
WealthShield Partners's Blueprint Medicines position peaked at $1K in Q1 2021.
281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.